PDF(Sci-hub)
Abstract：
Bladder cancer is the most common urinary tract malignancy. Platinum-based chemotherapy is the first line of treatment in locally advanced or metastatic bladder cancer. Immunotherapy has become a novel therapy option in a broad variety of malignancies including bladder cancer. Immunotherapy is approved as first line of treatment in patients who are ineligible for platinum-based chemotherapy and second-line treatment for metastatic urothelial cancer who progressed after platinum-based treatments. We present the case of an 83-year-old female with metastatic bladder cancer who was chemotherapy ineligible and had complete response with immune checkpoint inhibitor pembrolizumab.
摘要：
膀胱癌是最常见的尿路恶性肿瘤。基于铂的化疗是局部晚期或转移性膀胱癌的一线治疗。免疫治疗已成为包括膀胱癌在内的多种恶性肿瘤的新型治疗选择。免疫疗法被批准为不适合接受基于铂的化疗的患者的一线治疗和在基于铂的治疗后进展的转移性尿路上皮癌的二线治疗。我们介绍了一名83岁女性转移性膀胱癌的病例，该患者化疗不合格，免疫检查点抑制剂pembrolizumab完全应答。
